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Background: No studies have investigated the immediate impact of receiving an allogeneic hematopoietic stem
cell transplant (HSCT) on pulmonary inflammation or lung function.
Methods: Using a prospective study design, we quantified the changes in these outcome measures in eligible
adult individuals in the first six months after receiving an allogeneic hematopoietic stem cell transplant.
Results: Between January 2007 and December 2008, 72 patients were eligible to participate in the cohort, and of
these 68 (94%) were included in the study. Compared to baseline, pulmonary inflammation as measured by
exhaled nitric oxide increased after receiving a HSCT with the largest increment seen at three months (+6.0ppb,
95%CI: +0.4 to +11.5), and this was sustained at six months. Percent predicted forced expiratory volume in one
second decreased over the same period, with the largest decrease observed at six weeks (−5.9%, 95% CI: -8.9 to
−2.9), and this was also sustained over a six month period. Similar associations were observed for FVC. A larger
increase in exhaled nitric oxide from baseline at six weeks and three months may be associated with decreased
mortality (p=0.06, p=0.04 respectively).
Conclusion: Our data demonstrate that recipients of an allogeneic HSCT experience an increase in biomarkers of
pulmonary inflammation and a decrease in lung function in the first six months after the procedure. If
independently validated in other study populations, these observations could have potential as a prognostic
biomarker for this patient group.
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The use of allogeneic hematopoietic stem cell transplant
(HSCT) as a treatment for haematological malignancies is
increasing as the benefits of this intervention are applied
to a wider patient population [1]. However, although
this intervention is associated with a variety of pulmon-
ary complications, including infection and graft-versus-host
disease [2,3], most of the available data has utilised regular
lung function measures that are taken at least 6–12 months
after the allograft [4] or retrospective clinical studies [5,6].* Correspondence: andrew.fogarty@nottingham.ac.uk
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reproduction in any medium, provided the orThese do not give a detailed picture of the early effects on
the lung after receiving an allograft and in particular do not
quantify pulmonary inflammation during this time period.
This is important as 5-45% of deaths from allogeneic HSCT
(depending on indication) occur within 100 days after
receiving a HSCT [1] and the cause of death can often
be as a result of pulmonary complications [7]. Hence, in-
tensive monitoring of lung physiological outcome measures
may provide insights into the natural history of the impact
of receiving an allogeneic HSCT on the lungs, as well as
assessing if changes in respiratory function tests have
prognostic value. To be applicable in the clinical setting
such tests will need to be ideally readily deliverable
at regular clinic visits. We thus chose spirometry (Forced
Expiratory Volume in one second and Forced Vitall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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monary inflammation, as simple measures of lung
physiological health.
We have established a cohort of patients who received
an allogeneic HSCT and prospectively collected data on
lung function and exhaled nitric oxide to assess the
impact of this intervention on pulmonary function
and a biomarker of pulmonary inflammation. We have
also assessed if these outcomes are associated with
survival, and thus may provide a potential biomarker
that could be used to stratify patients who have received
a transplant.
Methods
Study population
Our study population consisted of 68 patients that had
received an allogeneic haematological stem cell trans-
plant (HSCT) in the Nottingham Regional Transplant
Centre between January 2007 and December 2009 as
standard treatment for their haematological disease. All
adult patients who received an allogeneic stem cell
transplant when staff were available for recruitment
and who had post-transplant follow-up in Nottingham
were eligible to participate in the study. The study was
approved by the Nottingham Regional Ethics Commit-
tee, and written consent was obtained from all subjects.
All myeloablative transplants received total body irradiation
of 12 to 14.4 Gy and cyclophosphamide 60mg/kg x 2days
while reduced intensity conditioning varied according to
the clinical condition.
Data collection
Approximately 1–2 weeks before the transplant, baseline
data were collected on sex, age, indication for transplant
and smoking history. The baseline data were collected
after chemotherapy treatment had started, but prior to
transplant. After transplant, the patients were assessed
during their routine clinical visits to the transplant clinic
at 6 weeks, 3 months and 6 months.
Pulmonary Function measurements were performed
using a Vitalograph 2120 spirometer (Vitalograph Ltd,
Buckingham, England). Forced vital capacity in one sec-
ond (FEV1) and Forced Vital Capacity (FVC), were
measured according to ERS/ATS criteria [8], and compared
with predicted values from the European Community for
Steel and Coal normal range [9]. Fractional exhaled nitric
oxide (FENO) measurements were made using an NIOX
MINO portable analyser (Aerocrine AB, Stockholm,
Sweden), an electrochemical analyser, at a sample rate
of 50 mL/min. FENO measurements were performed
prior to spirometry. Patients were instructed not to eat
or drink for a minimum of one hour prior to testing.
Patients were seated at rest, for at least 20 min prior to
the test and results were recorded in parts per billion(PPB). The initial study proposal aimed to look at the
short-term changes in lung function after receiving an
allograft HSCT, and we were subsequently also able to
later collect data on pulmonary inflammation after
starting data collection.
Statistical methods
The data were analysed using Cox Regression to assess
the association of the lung measurements with subse-
quent survival. As well as presentation of mean changes
in lung function and exhaled nitric oxide as measured
by paired t-tests, the proportion of individuals whose
lung function decreased by more than 15% or whose
exhaled nitric oxide increased by 10ppb or more are
presented, to give a more complete presentation of
those who experienced large changes in the pulmonary
measures of interest. The start time for the survival ana-
lysis was the date of the HSCT and the final date was
the last date when the individual was followed up in
clinic or the date of death. In the survival analysis, sex,
age and smoking status were added to the model as a
priori potential confounding factors. The proportional
hazards assumption for the survival analysis was tested
to ensure that these were not contravened. All statistical
analyses were done utilising STATA 11.0 (Texas, USA).
The numbers of patients followed up decreased with
time as a consequence of mortality.
Results
Between January 2007 and December 2008, 72 patients
received an allogeneic transplant for haematological
malignancy at the Nottingham Regional Transplant Centre
and were eligible for the study. Of these, 68 (94%) patients
agreed to participate in the study and 4 (6%) patients
refused to consent to the study (Table 1).
After allogeneic HSCT, the lung function as measured
by percent predicted FEV1 decreased at six weeks (− 5.9%,
95% confidence intervals CI: -8.9 to −2.9), three months
(−4.7%, 95%CI: -8.4 to −1.0) and six months (−4.3%, 95%
CI: -7.7 to −0.9) compared to baseline (Table 2). Similar
results were seen for percent predicted FVC over the
same time period. After receiving an allogeneic HSCT
(Table 2), exhaled nitric oxide was increased at six weeks
(+2.1ppb 95% CI: -1.8 to +5.9), three months (+6.0ppb,
95% CI: +0.4 to +11.5) and six months +6.4ppb (95% CI:
+0.7 to +12.1). However, the baseline exhaled nitric oxide
was not predictive of the change in FEV1 at three months
or six months (data not shown).
Subgroup comparison between those who received
full myloablative conditioning and those who received
reduced intensity conditioning for revealed no consist-
ent differences between the two groups for lung func-
tion or exhaled nitric oxide, although at three months
those who received the reduced intensity conditioning
Table 1 Characteristics of the allograft recipients in
the study
Total no. of individuals in cohort 68
Male (%) 34 (50)
Mean age at transplant, sd 48.5 years (13.2)
Smoking status (%)
Never 19 (28)
Ex-smoker 43 (63)
Current smoker 6 (9)
Diagnosis at HSCT (%)
AML 33 (49)
ALL 8 (12)
Non Hodgkin’s Lymphoma 5 (7)
Hodgkin’s Lymphoma 5 (7)
Myelodysplastic syndrome 4 (6)
Chronic lymphatic leukaemia 4 (6)
Other* 9 (13)
Donor type (%)
Matched unrelated donor 42 (62)
Cord blood 4 (6)
Sibling 22 (32)
Stem Cell Source (%)
Peripheral blood stem cell source 54 (80)
Bone marrow 10 (16)
Umbilical cord 4 (6)
Type of Conditioning prior to HSCT (%)
Myeloablative conditioning 23 (34)
Reduced intensity 45 (66)
HSCT Haematopoietic stem cell transplant.
Sd Standard deviation.
Ppb Parts per billion.
* other (n) = aplastic anaemia (1), chronic myelomonocytic leukaemia (1),
chronic myeloid leukaemia (2), multiple myeloma (3) and mantle cell
lymphomas (2).
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+0.1 to +15.2) and FVC (+9.4; 95%CI: +1.6 to +17.1)
compared to those who did not receive reduced inten-
sity conditioning.
In the survival analysis, there were 22942 days of total
analysis time at risk and 22 deaths during this period.
After adjustment for sex, age and smoking status, there
was an inverse association between change in exhaled
NO from baseline to six weeks and risk of death (Hazard
Ratio HR 0.95 per unit of exhaled NO, 95% CI: 0.90 to
1.00, p=0.06) and three months (HR 0.94 per unit of
exhaled NO, 95% CI: 0.89 to 1.00, p=0.04) for those
individuals who provided paired data. There was no as-
sociation between risk of death and change in lung func-
tion at the same time points after adjusting for the same
covariates (data not shown).Discussion
This is the first study to explore the early changes in lung
function and pulmonary inflammation in a cohort of
individuals who had undergone an allogeneic hematopoietic
stem cell transplant. Our data demonstrate that lung func-
tion decreases and pulmonary inflammation increases after
receiving an allogeneic HSCT. The change in exhaled nitric
oxide may have potential in the stratification of patients
for subsequent risk of mortality, and we consider that this
is worth consideration in future cohort studies assessing
potential biomarkers in this patient group.
One strength of our data is its high response rate, with
94% of eligible patients being enrolled in the cohort and
only 6% of eligible patients declining to provide data.
We were subsequently able to follow up the patients and
collect detailed information on their changes in lung
function and pulmonary inflammation, and also collect
data on potential confounding factors and mortality. As
our measurements were collected by a single person in
a standardised manner, we are confident in that we have
minimised the bias that can be introduced by multiple
observers collecting data. The collection of data from
a single centre which all patients who live in the
surrounding centre attend ensures that the mortality
data is complete.
Our study has a variety of limitations that require con-
sideration. Having elected to collect detailed data on
lung function and pulmonary inflammation, the study
necessarily had to be from only one transplant centre
due to staffing constraints. This has limited the number
of participants that we were able to recruit and hence
the power of the study to detect clinically important
associations. However, this is the largest study to meas-
ure lung function and pulmonary inflammation in this
patient cohort during the early months after receiving
an allogeneic HSCT, and the 95% confidence intervals in
our data should be useful in guiding researchers and
clinicians in the future of the potential of these outcome
measures in managing these patients. Unfortunately,
we were unable to collect more detailed data on lung
function including transfer factor due the logistical
challenges of doing time-intensive measurements in a
group of patients who are already debilitated from the
HSCT. The generalisability of these data should be
good for populations that are similar in age, initial dis-
ease and HSCT treatment regimens. As we have a rela-
tively small study population and have tested a number
of hypotheses, we are unable to exclude the possibility
that some of the apparently significant associations
observed may be spurious as a consequence of multiple
hypothesis testing.
Previous research on the impact of receiving an allo-
geneic HSCT has tended to use routinely collected data
at clinic visits, which is a powerful approach allowing
Table 2 Change in lung function and pulmonary inflammation occurring after receiving an allograft haematopoietic
stem cell transplant
Time after stem cell transplant
Baseline 6 weeks 3 months 6 months
Mean percent predicted FEV1 (sd) 90.3 (15.8) 84.0 (18.9) 86.0 (19.6) 85.5 (19.4)
N=68 N=64 N=57 N=47
Change in percent predicted FEV1 from baseline (95% CI) - - 5.9 −4.7 −4.3
(−8.9 to −2.9) (−8.4 to −1.0) (−7.7 to −0.9)
p<0.001 p=0.007 p=0.007
Number with decrease in predicted FEV1 by ≥15% (%) - 10 10 8
(16) (18) (17)
Mean percent predicted FVC (sd) 98.6 (15.7) 91.4 (18.1) 93.1 (18.6) 94.1 (17.1)
N=68 N=61 N=56 N=47
Change in FVC from baseline(95% CI) −6.4 −5.3 −5.6
- (−9.7 to −3.0) (−9.1 to −1.5) (−9.1 to −2.2)
p<0.001 p=0.008 p=0.002
Number with decrease in predicted FVC by ≥15% (%) - 15 10 11
(25) (18) (23)
FEV1/FVC (sd) 76 (9) 76 (10) 77 (9) 76 (11)
N=68 N=61 N=56 N=47
Median exhaled nitric oxide, ppb, (IQR) 15 (12–25) 18.5 (12–27) 19 (15–28) 20 (16–27)
N=59* N=54* N=43* N=38*
Change in exhaled nitric oxide from baseline, ppb (95% CI) +2.1 +6.0 +6.4
- (−1.8 to +5.9) (+0.4 to +11.5) (+0.7 to +12.1)
p=0.283 p=0.034 p=0.028
N=48 N=40 N=36
Number with increase in exhaled NO by ≥10ppb (%) - 10 11 13
(21) (27) (36)
FEV1- Forced Expiratory Volume in one second.
FVC- Forced Vital Capacity.
CI- Confidence intervals.
IQR- Interquartile range.
NO= Nitric oxide.
* the numbers of patients with exhaled nitric oxide measurements are lower then those with lung function as this was added after data collection had begun.
Statistical comparisons using paired t-tests.
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gest previous study by Chien et al. demonstrated that
new airflow obstruction (as defined as a more than 5%
annual decline in FEV1 with the lowest post-transplant
FEV1/FVC ratio of less than 0.8) was 26%, and
associated with higher mortality rates at follow up than
those with no airflow obstruction [4]. However, this im-
portant study did not look at pulmonary function tests
within 6 months of receiving a HSCT, and hence is not
directly comparable with our data. Savani et al. [10]
studied patients who survived for five years or more
after HSCT, and reported that chronic graft-versus-host
disease (GVHD) and low FEV1 and diffusion capacity
for carbon monoxide were associated with a decrease in
pulmonary function. As this study described a survivorcohort with a long follow up period, again direct
comparisons with our data are impossible. Similarly,
Lund et al. [5] studied 43 patients who survived for five
years and reported a decrease in lung function and
transfer factor in the first year which returned to base-
line after five years, and again these data are hence in a
survivor cohort and not directly comparable to our data.
A recent study looking at 33 patients, approximately
one year after HSCT suggested that peripheral airways
heterogeneity may be a better measure that could be
more sensitive than simple lung function measurements
such as FEV1 in detecting early lung pathology [11].
To our knowledge no other studies have looked at the
impact of receiving an allogeneic HSCT on pulmonary
inflammation in adults in the six months after the
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observed after HSCT may be a consequence of either the
conditioning or the result of an immunological or inflam-
matory response to the allograft, and the absence of a con-
sistent difference between the two conditioning groups
suggests that the latter explanation may be more likely,
although the study was not powered to examine these
differences. The inverse association between change in
exhaled NO from baseline at six weeks and three months
with subsequent mortality was unexpected and needs to
be considered with caution as the numbers of patients
studied were small and these relationships may have
occurred by chance as we have tested a number of
associations in this analysis (p=0.04 to 0.06). Nonethe-
less, this is an interesting observation worth consider-
ation. Exhaled nitric oxide is a measure of pulmonary
inflammation [12], and the inflammatory response in
general probably evolved to help host organisms fight
infection [13]. A recent study in 30 children with a
mean age of 12 years suggests that higher exhaled nitric
oxide is associated with pulmonary complications (pre-
dominantly infections) 28 days after receiving a HSCT
[14], demonstrating that this biological response is active
in the early period after receiving a HSCT. Hence, we
cautiously speculate that the inverse association be-
tween change in pulmonary inflammation and mortality
observed in our dataset, if a true phenomenon, may be a
consequence of an impaired ability to generate an inflam-
matory response, which may then result in increased sus-
ceptibility to infections in this patient group.
By adding to the literature of the relatively short-term
consequences of receiving an allogeneic HSCT on the
lungs, we have observed associations and hence generated
hypotheses that now require consideration in other
populations. The identification of biomarkers for pulmon-
ary disease and mortality in individuals who have received
an allogeneic HSCT is important as it will allow the
early identification of those who are at high risk for
these complications. This can then permit more inten-
sive monitoring of this patient group and possibly also
stratification to allow better targeted trials of interventions
that can modify disease progression without exposing
individuals who are less likely to develop these compli-
cations to the potential adverse side-effects that can ac-
company many therapeutic interventions.Conclusions
In summary, we have demonstrated in a representative
sample of patients who received an allogeneic HSCT that
pulmonary inflammation increases in the first six months
after the procedure while lung function decreases over the
same time period. We hope that future research in this
area will examine these associations in larger numbers ofpatients that will provide more power to determine the
clinical importance of these associations.
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